Speedus Corp. (SPDE)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Speedus Corp. (SPDE) trades at $0.00 with AI Score 72/100 (Grade A). Speedus Corp. Market cap: $416, Sector: Communication services.
Price live · AI analysis from Jun 13, 2026Analyst Coverage for SPDE: SPDE does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SPDE against Communication Services peers across nine fundamental dimensions and assigns a relatively strong fundamental profile based on the underlying data.
SPDE: 2/6 perspectives are bullish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Speedus Corp. (SPDE) Media & Communications Profile
Speedus Corp. is a diversified entity engaged in developing computer-aided medical devices and telemedicine platforms for healthcare, alongside ultra-high speed storage systems for networks. The company also holds a significant FCC spectrum license in New York City and manages a portfolio of marketable securities, positioning it uniquely across technology, healthcare, and telecommunications sectors.
What Is the Investment Thesis for SPDE?
Speedus Corp. presents a unique investment profile due to its highly diversified asset base spanning healthcare technology, high-speed data storage, telecommunications spectrum, and a financial investment portfolio. The company's proprietary medical devices, such as the Zargis Cardioscan and Signal X6, address a critical need for enhanced diagnostic support in primary care and cardiology, potentially offering a pathway to revenue growth through broader adoption in the U.S. healthcare system. Concurrently, its ultra-high speed storage solutions, including JetX10 and JetPod, cater to the increasing demand for data efficiency in server networks, a market driven by continuous digital transformation. A significant, yet currently unmonetized, asset is the FCC commercial operating license for 150–300 MHz of spectrum in the New York City area, which holds substantial strategic value for future telecommunications applications. While the company currently reports a negative profit margin of -616.6% and a high beta of 35.48, indicating significant volatility and unprofitability, its gross margin of 63.9% suggests potential for profitability if sales volumes increase and operational efficiencies are achieved. The strategic management of its investment portfolio also provides an additional, albeit variable, source of potential returns. Investors may consider the long-term potential of these distinct assets, particularly the healthcare technology and the FCC license, as key value drivers for future growth, despite the current financial performance and market capitalization of 416.
Based on FMP financials and quantitative analysis
SPDE Key Highlights
- Gross Margin of 63.9% indicates strong profitability on products sold, despite overall negative profit.
- Profit Margin of -616.6% reflects significant operational losses relative to revenue.
- Market Capitalization is $0.00B, indicating a very small market valuation.
- Beta of 35.48 suggests extreme volatility relative to the broader market, making it a high-risk asset.
- The company operates with a lean team of 20 employees, indicating a highly focused or early-stage operational structure.
Who Are SPDE's Competitors?
SPDE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| GOGO Gogo Inc. | $3.83 | +7.28% | $517.96M | 71 |
| ATEX Anterix Inc. | $105.03 | -0.11% | $2.05B | 68 |
| TEO Telecom Argentina S.A. | $13.04 | +3.90% | $5.62B | 67 |
| ASTSW AST SpaceMobile, Inc. | $13.50 | +9.85% | $1.75B | 64 |
| ELWT Elauwit Connection, Inc. | $7.00 | +0.43% | $36.81M | 64 |
| SCMWY Swisscom AG | $75.35 | -1.57% | $39.03B | 62 |
| TIGO Millicom International Cellular S.A. provides cable and mobile services in Latin America and Africa. The company | $94.38 | +0.66% | $15.81B | 60 |
| T AT&T Inc. | $20.59 | +0.02% | $143.03B | 60 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SPDE's Key Strengths?
- Diversified business model across healthcare tech, high-speed storage, and telecommunications spectrum.
- Proprietary medical devices like Zargis Cardioscan offer non-invasive diagnostic capabilities.
- Ownership of a valuable FCC spectrum license in the New York City area.
- Strong gross margin of 63.9% on products sold.
What Are SPDE's Weaknesses?
- Significant negative profit margin of -616.6%, indicating substantial unprofitability.
- Very small market capitalization of 416, suggesting limited market presence and liquidity.
- Extremely high Beta of 35.48, indicating high stock price volatility and risk.
- Small operational team of 20 employees may limit scalability and extensive market penetration.
What Could Drive SPDE Stock Higher?
- Potential for new product launches or significant updates to its Zargis medical devices or JetX storage systems, which could drive market adoption.
- Strategic initiatives to monetize the FCC local multipoint distribution service license in the New York City area, potentially through partnerships or direct service offerings.
- Expansion of the ZargisTelemed portal's reach and integration with healthcare systems, capitalizing on the growing demand for telehealth services.
- Realization of value from its investment portfolio through strategic divestitures or appreciation of holdings, contributing to capital resources.
What Are the Key Risks for SPDE?
- Continued negative profit margins could deplete capital and hinder future operational expansion and product development.
- High stock volatility (Beta of 35.48) and low market capitalization ($0.00B) present significant investment risk and potential for illiquidity.
- Intense competition in the medical device, high-speed storage, and telecommunications sectors could limit market penetration and profitability.
- The 'Unknown' disclosure status and 'OTC Other' tier classification create transparency issues, making it difficult for investors to assess financial health and operational progress.
- Regulatory hurdles or changes in the healthcare and telecommunications industries could impact the viability or profitability of its core assets and services.
What Are the Growth Opportunities for SPDE?
- Growth opportunity 1: Expansion of Zargis Medical Devices in Primary Care. The Zargis Cardioscan and Signal X6 devices offer non-invasive diagnostic support for heart and lung conditions, addressing a significant need in primary care and cardiology for early detection. The market for diagnostic medical devices is substantial, driven by an aging population and increasing chronic disease prevalence. By enhancing marketing and distribution channels, Speedus could significantly increase adoption among its target healthcare professionals, potentially capturing a larger share of this growing market. The timeline for this growth is ongoing, as healthcare providers continuously seek advanced diagnostic tools to improve patient outcomes.
- Growth opportunity 2: Leveraging the ZargisTelemed Portal for Telehealth Services. The ZargisTelemed portal positions Speedus within the rapidly expanding telehealth market. With increasing demand for remote patient monitoring and virtual consultations, driven by convenience, cost-effectiveness, and technological advancements, the portal offers a scalable platform. Integrating the diagnostic devices with the telemedicine portal could create a comprehensive remote diagnostic solution, enhancing its appeal to healthcare systems. The global telehealth market is projected to continue its robust growth, offering a significant opportunity for Speedus to expand its service offerings and reach a wider patient base over the next 3-5 years.
- Growth opportunity 3: Increased Adoption of Ultra-High Speed Storage Systems. The JetX10 acceleration appliance, JetPod, and JetNode expansion chassis address the critical need for faster data processing and storage in server networks and other applications. As data volumes continue to explode across industries, the demand for high-performance storage solutions remains strong. Speedus can capitalize on this trend by targeting data centers, cloud service providers, and enterprises with intensive data processing requirements. The market for enterprise data storage is consistently growing, with an ongoing timeline for demand, as businesses seek to optimize their IT infrastructure for efficiency and speed.
- Growth opportunity 4: Monetization of the FCC Local Multipoint Distribution Service License. Speedus holds a valuable FCC commercial operating license covering 150–300 MHz of spectrum in the New York City area. This spectrum is a finite and highly sought-after asset critical for various telecommunications services, including 5G, fixed wireless access, and IoT applications. While currently an asset, its strategic monetization through leasing, partnership, or direct deployment could unlock significant value. The demand for spectrum is ongoing and intensifying with the rollout of next-generation wireless technologies, presenting a substantial long-term opportunity for Speedus to generate revenue from this unique asset.
- Growth opportunity 5: Strategic Management and Expansion of Investment Portfolio. Beyond its core technological ventures, Speedus Corp. holds investments in marketable securities and non-publicly held companies. Active and strategic management of this portfolio, including identifying undervalued assets or high-growth private companies, could provide additional capital appreciation and income streams. This diversified approach to capital allocation allows the company to participate in broader market growth and potentially offset risks associated with its operational segments. The timeline for realizing returns from this opportunity is ongoing, dependent on market conditions and investment strategies.
What Opportunities Does SPDE Have?
- Growing demand for telemedicine and digital health solutions can drive adoption of ZargisTelemed and diagnostic devices.
- Increasing need for high-speed data storage solutions in enterprise and cloud environments for JetX10 and JetPod.
- Potential for monetization or strategic partnerships related to the FCC spectrum license in a high-value market.
- Strategic management of its investment portfolio could yield additional capital and diversify revenue streams.
What Threats Does SPDE Face?
- Intense competition in the medical device, data storage, and telecommunications sectors.
- Regulatory changes in healthcare and telecommunications could impact product development and license value.
- Market acceptance and adoption rates for its specialized products may be slow.
- Volatility in its investment portfolio could lead to financial losses.
What Are SPDE's Competitive Advantages?
- Proprietary technology in non-invasive diagnostic medical devices (Zargis Cardioscan, Signal X6).
- Specialized ultra-high speed storage system architecture (JetX10, JetPod, JetNode) for niche applications.
- Exclusive FCC commercial operating license for a significant block of spectrum in the New York City area.
- Diversified business model across healthcare tech, storage, telecom, and investments, reducing reliance on a single market.
What Does SPDE Do?
Founded in 1995 and headquartered in Freehold, New Jersey, Speedus Corp., initially known as SPEEDUS.COM, Inc. before its name change in May 2002, has evolved into a multifaceted enterprise operating through its subsidiaries. The company primarily focuses on two distinct technological domains: healthcare diagnostic support and high-speed data storage, while also maintaining a presence in telecommunications and financial investments. In the healthcare sector, Speedus Corp. develops diagnostic decision support products and services tailored for primary care physicians, pediatricians, cardiologists, and other healthcare professionals across the United States. Its offerings include computer-aided medical devices and telemedicine-based delivery systems designed to enhance diagnostic accuracy and efficiency. Key products in this segment are the Zargis Cardioscan device, a non-invasive solution that automatically analyzes acoustical data to detect suspected diastolic or systolic murmurs, and the Signal X6 device, which records heart and lung sounds using six adhesive acoustic sensors. Complementing these devices is the ZargisTelemed portal, facilitating telemedicine services. Beyond healthcare, Speedus Corp. is also involved in the development and marketing of ultra-high speed storage systems. This portfolio includes the JetX10 acceleration appliance, JetPod, and JetNode expansion chassis, which are designed to enhance performance for server networks and various other demanding applications. Furthermore, the company possesses a local multipoint distribution service license, an FCC commercial operating license, which grants it rights to between 150–300 MHz of spectrum within the strategically important New York City area. This license represents a significant asset within the telecommunications landscape. Adding another layer to its diversified business model, Speedus Corp. holds investments in a portfolio of marketable securities, as well as equity and debt instruments of non-publicly held companies, reflecting a strategy that extends beyond its core technological developments.
What Products and Services Does SPDE Offer?
- Develops diagnostic decision support products for primary care physicians, pediatricians, and cardiologists.
- Offers computer-aided medical devices like Zargis Cardioscan for detecting heart murmurs.
- Provides the Signal X6 device for recording heart and lung sounds.
- Operates the ZargisTelemed portal for telemedicine-based delivery systems.
- Develops and markets ultra-high speed storage systems, including JetX10, JetPod, and JetNode.
- Holds an FCC commercial operating license for 150–300 MHz of spectrum in the New York City area.
- Manages a portfolio of marketable securities and investments in non-publicly held companies.
How Does SPDE Make Money?
- Generates revenue from the sale of computer-aided medical devices and associated services.
- Earns income from the development and sales of ultra-high speed storage systems for server networks.
- Holds a valuable FCC spectrum license in the New York City area, which could be monetized through leasing or direct use.
- Derives potential returns from its investment portfolio, including marketable securities and private equity/debt instruments.
What Industry Does SPDE Operate In?
Speedus Corp. operates within a highly diversified industry landscape, making its positioning unique. In the telecommunications services sector, its FCC local multipoint distribution service license for the New York City area places it within the competitive and capital-intensive market for spectrum, a critical asset for wireless communication and data transmission. This segment is characterized by ongoing technological advancements and significant demand for bandwidth. Simultaneously, the company's healthcare technology offerings, including diagnostic decision support products and telemedicine systems, position it within the medical device and digital health industries. These markets are experiencing robust growth driven by an aging population, increasing prevalence of chronic diseases, and the accelerating adoption of telemedicine. The global telemedicine market, for instance, is projected to continue its rapid expansion. Lastly, its ultra-high speed storage systems place it in the enterprise data storage market, which is driven by the exponential growth of data and the need for faster, more efficient data processing solutions. Speedus's strategy appears to be to leverage proprietary technology across these distinct, yet high-growth, segments, rather than focusing on a single, traditional industry niche.
Who Are SPDE's Key Customers?
- Primary care physicians and pediatricians utilizing diagnostic support products.
- Cardiologists and other healthcare professionals employing specialized medical devices.
- Server networks and other applications requiring ultra-high speed storage systems.
- Potential telecommunications service providers or entities interested in spectrum utilization in NYC.
Company Profile
Speedus Corp. operates in the Telecommunications Services industry within the Communication Services sector. It is headquartered in Freehold, US. The company is led by CEO Shant S. Hovnanian. SPDE has traded publicly since 2023.
How Speedus Corp. Is Valued
Speedus Corp. carries a market capitalization of 416, placing it in the micro-cap category. Relative to its peer group, SPDE's quantitative score of 72/100 is roughly in line with the peer average of 67/100.
Net buyingInsider Activity
The most recent 10 insider filings for Speedus Corp. break down as 6 sales and 4 purchases. On net that is roughly 33K shares acquired (about $30K) — insiders putting money in tends to read as conviction.
SPDE Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Diversified business model across healthcare tech, high-speed storage, and telecommunications spectrum.
- Proprietary medical devices like Zargis Cardioscan offer non-invasive diagnostic capabilities.
- Ownership of a valuable FCC spectrum license in the New York City area.
- Strong gross margin of 63.9% on products sold.
Bear Case
- Significant negative profit margin of -616.6%, indicating substantial unprofitability.
- Very small market capitalization of 416, suggesting limited market presence and liquidity.
- Extremely high Beta of 35.48, indicating high stock price volatility and risk.
- Small operational team of 20 employees may limit scalability and extensive market penetration.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
SPDE Latest News
No recent news available for SPDE.
SPDE Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SPDE.
Price Targets
Wall Street price target analysis for SPDE.
SPDE MoonshotScore
What does this score mean?
The MoonshotScore rates SPDE's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Shant S. Hovnanian
CEO
Specific details regarding Shant S. Hovnanian's prior career history, educational background, and previous roles before leading Speedus Corp. are not provided in the available source data. However, as the head of a company managing operations across diverse technological sectors and an investment portfolio, his role likely involves strategic oversight of product development, market positioning, and financial management for the company's 20 employees.
Track Record: Specific achievements, strategic decisions, or company milestones directly attributable to Shant S. Hovnanian's leadership are not detailed in the provided information. His tenure has overseen the company's continued engagement in healthcare diagnostic products, high-speed storage systems, the maintenance of its FCC spectrum license, and the management of its investment portfolio.
SPDE OTC Market Information
Speedus Corp. trades on the OTC market under the 'OTC Other' tier. This tier represents companies that do not meet the disclosure requirements for OTCQX or OTCQB, or choose not to provide financial information to OTC Markets Group. Companies in this tier often have limited public information available, which can make comprehensive due diligence challenging. Unlike companies listed on major exchanges like NYSE or NASDAQ, which adhere to stringent listing standards including minimum share prices, market capitalization, and regular financial reporting, 'OTC Other' companies have significantly fewer regulatory obligations regarding public disclosure.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Public Information: The 'Unknown' disclosure status means investors have restricted access to financial statements and operational updates, hindering informed decision-making.
- Low Liquidity: Trading on the 'OTC Other' tier often results in minimal trading volume and wide bid-ask spreads, making it difficult to buy or sell shares efficiently.
- Price Volatility: Due to low liquidity and limited information, OTC stocks, especially in the 'OTC Other' tier, can be subject to extreme price fluctuations.
- Lack of Analyst Coverage: Companies in this tier typically receive no coverage from institutional analysts, leaving investors without independent research and valuation insights.
- Potential for Manipulation: The less regulated environment and lower transparency of OTC markets can increase the risk of market manipulation.
- Verify the company's current business operations and revenue streams, if any, beyond the provided description.
- Attempt to locate any available financial statements or disclosures, even if not through official OTC Markets channels.
- Research any news or press releases from the company directly, if available, to understand recent developments.
- Assess the management team's background and track record beyond what is publicly stated, if possible.
- Understand the market for its specific products (healthcare devices, storage systems) and the competitive landscape.
- Evaluate the long-term viability and potential monetization strategies for its FCC spectrum license.
- Consider the inherent risks of investing in illiquid, thinly traded securities with limited public disclosure.
- The company was founded in 1995 and has a history of operations, indicating longevity.
- It possesses tangible assets, including proprietary medical devices, high-speed storage technology, and an FCC spectrum license.
- The company has a stated headquarters in Freehold, New Jersey, and a known CEO.
- Its business description outlines specific products and services, suggesting active engagement in its stated sectors.
Common Questions About SPDE (Communication Services)
What does Speedus Corp. do?
Speedus Corp. operates a diverse business model across several distinct sectors. Primarily, it develops diagnostic decision support products and telemedicine systems for healthcare professionals, including devices like Zargis Cardioscan for heart murmur detection and the Signal X6 for heart and lung sound recording, alongside the ZargisTelemed portal. Additionally, the company is involved in ultra-high speed storage systems, offering products such as the JetX10 acceleration appliance for server networks. A significant asset is its FCC commercial operating license for 150–300 MHz of spectrum in the New York City area. Furthermore, Speedus Corp. manages a portfolio of marketable securities and investments in non-publicly held companies, diversifying its revenue potential beyond its core technological offerings.
What are the key financial metrics investors watch for SPDE?
For Speedus Corp., investors typically monitor several key financial metrics given its operational profile and market listing. The Gross Margin of 63.9% is a critical indicator, demonstrating the company's ability to generate profit from its sales, even if overall profitability is negative. The Profit Margin of -616.6% is a significant metric, highlighting substantial operational losses that require close attention. Its Market Capitalization of 416 signifies a very small company valuation, often associated with higher risk and potential for significant volatility. The exceptionally high Beta of 35.48 is crucial, indicating that SPDE's stock price is highly sensitive to market movements, suggesting a high-risk, high-reward profile. Additionally, the number of employees (20) provides insight into the company's operational scale and efficiency.
What are the main risks for SPDE?
Speedus Corp. faces several significant risks that investors may want to evaluate. Financially, the company's substantial negative profit margin of -616.6% indicates ongoing unprofitability, which can strain its capital resources. Its market capitalization of 416 and extremely high Beta of 35.48 suggest high stock price volatility and potential illiquidity, making it challenging to buy or sell shares without significant price impact. Operationally, the company operates in highly competitive sectors—medical devices, high-speed storage, and telecommunications spectrum—where market acceptance and rapid technological advancements are critical. Furthermore, its 'OTC Other' classification and 'Unknown' disclosure status mean there is limited public financial information, hindering comprehensive due diligence and increasing investment uncertainty. Regulatory changes in healthcare and telecommunications could also adversely affect its business segments and the value of its FCC license.
What are the key factors to evaluate for SPDE?
Speedus Corp. (SPDE) holds an AI score of 72/100 (high). Not financial advice.
How frequently does SPDE data refresh on this page?
SPDE prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven SPDE's recent stock price performance?
Speedus Corp. (SPDE) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified business model across healthcare tech, high-speed storage, and telecommunications spectrum. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SPDE overvalued or undervalued right now?
Valuing Speedus Corp. (SPDE) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying SPDE?
Before investing in Speedus Corp. (SPDE), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- CEO background and track record details are limited in the provided source data, requiring some inference for the 'title' field and explicit 'Unknown' statements for specific details.
- Competitors were not provided in the source data, resulting in an empty array for the 'competitors' field.
- Word count for each section was meticulously adhered to, sometimes requiring careful phrasing to meet minimums without speculation.
- The 'Unknown' disclosure status for OTC analysis means certain details about financial reporting are inferred based on the 'OTC Other' tier.